# Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

> **NCT03452228** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Severe Hypertriglyceridemia (sHTG)

## Interventions

- **DRUG:** evinacumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03452228
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-07
- **Primary completion:** 2019-12-17
- **Final completion:** 2020-07-23
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452228, "Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03452228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*